Canaccord raised the firm’s price target on Castle Biosciences (CSTL) to $42 from $35 and keeps a Buy rating on the shares. The firm said they are bullish heading into earnings and 2025 as recent weakness has provided an opportunity to accumulate shares ahead of upcoming catalysts or underappreciated positve factors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTL:
- Castle Biosciences: MyPath Melanoma GEP test providies accurate diagnosis
- Castle Biosciences price target raised to $40 from $35 at BTIG
- BTIG life sciences/diagnostics analyst holds an analyst/industry conference call
- Castle Biosciences: DecisionDx -Melanoma can precise predict SLN positivity risk
- Castle Biosciences: New study shows DecisionDx-SCC test benefits SCC patients